An Essential Role for IFN-γ in Regulation of Alloreactive CD8 T Cells Following Allogeneic Hematopoietic Cell Transplantation Wannee Asavaroengchai,

Slides:

Advertisements

Similar presentations

Joseph H. Chewning, Weiwei Zhang, David A. Randolph, C

Advertisements

Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation Qing Ma, Dan Li, Roza Nurieva, Rebecca.

Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation Michael Weber,

William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D

Depletion of Naïve Lymphocytes with Fas Ligand Ex Vivo Prevents Graft-versus-Host Disease without Impairing T Cell Support of Engraftment or Graft-versus-Tumor.

The Fifth Epidermal Growth Factor–like Region of Thrombomodulin Alleviates Murine Graft-versus-Host Disease in a G-Protein Coupled Receptor 15 Dependent.

Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation:

Expression of Chemokines in GVHD Target Organs Is Influenced by Conditioning and Genetic Factors and Amplified by GVHR Markus Y. Mapara, Corinna Leng,

Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,

Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4+ T Cells after Allogeneic Stem Cell Transplantation

Host-Derived Interleukin-18 Differentially Impacts Regulatory and Conventional T Cell Expansion During Acute Graft-Versus-Host Disease Robert Zeiser,

Extracorporeal Photopheresis Attenuates Murine Graft-versus-Host Disease via Bone Marrow–Derived Interleukin-10 and Preserves Responses to Dendritic Cell.

IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy

Identification of Stem Cell Transcriptional Programs Normally Expressed in Embryonic and Neural Stem Cells in Alloreactive CD8+ T Cells Mediating Graft-versus-Host.

Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A

Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver Alina Schreder,

Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine Weiqing Jing,

Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J

Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation Jian-ming Li, John Gorechlad,

William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D

Volume 44, Issue 1, Pages (January 2016)

Preventive Azithromycin Treatment Reduces Noninfectious Lung Injury and Acute Graft- versus-Host Disease in a Murine Model of Allogeneic Hematopoietic.

Ex Vivo Rapamycin Generates Th1/Tc1 or Th2/Tc2 Effector T Cells With Enhanced In Vivo Function and Differential Sensitivity to Post-transplant Rapamycin.

LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.

Cytosine-Phosphorothionate-Guanine Oligodeoxynucleotides Exacerbates Hemophagocytosis by Inducing Tumor Necrosis Factor–Alpha Production in Mice after.

Altered Homeostasis of CD4+ Memory T Cells in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Chronic Graft-versus-Host Disease Enhances T Cell.

The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease by Shan He, Fang.

by Sheng F. Cai, Xuefang Cao, Anjum Hassan, Todd A

Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation Yang Wang, Dan Li, Dan Jones, Roland.

Growth and Differentiation Advantages of CD4+OX40+ T Cells from Allogeneic Hematopoietic Stem Cell Transplantation Recipients Takero Shindo, Takayuki.

IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation Lucrezia Colonna, Mareike.

Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators Shoshana.

The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality Kai Sun,

Evelyn C. Nieves, Tomomi Toubai, Daniel C

Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.

Tatjana Banovic, Kelli P. A. MacDonald, Kate A. Markey, Edward S

Volume 22, Issue 12, Pages (December 2014)

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease by Tangsheng Yi, Dongchang Zhao, Chia-Lei.

Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host.

Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens Hisaki Fujii,

Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses William H.D. Hallett, Erik Ames, Maite.

Survival and Function of MiHA Epitope-Specific Host CD8 TM Cells Following Ablative Conditioning and HCT Alwi M. Shatry, Derry C. Roopenian, Robert B.

Enrichment of IL-12–Producing Plasmacytoid Dendritic Cells in Donor Bone Marrow Grafts Enhances Graft-versus-Leukemia Activity in Allogeneic Hematopoietic.

Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.

Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,

T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.

Volume 132, Issue 1, Pages (January 2007)

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease Isao Tawara,

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.

Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice Dapeng Wang, Yu Yu, Kelley Haarberg,

Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease Haruko Sugiyama,

A CD4 Domain 1 CC′ Loop Peptide Analogue Enhances Engraftment in a Murine Model of Bone Marrow Transplantation with Sublethal Conditioning Gabor Varadi,

Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation

Elevation of Intracellular Cyclic AMP in Alloreactive CD4+ T Cells Induces Alloantigen- Specific Tolerance That Can Prevent GVHD Lethality In Vivo Matthew.

Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.

In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.

B Cells and Transplantation: An Educational Resource

Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.

CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease Philip R Streeter,

Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation Jian-Ming Li, Edmund K.

Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

Volume 17, Issue 2, Pages (February 2009)

Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:

Specific donor Vβ-associated CD4+ T-cell responses correlate with severe acute graft- versus-host disease directed to multiple minor histocompatibility.

Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease Wonyoung Kim, Juyang.

Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.

Volume 37, Issue 2, Pages (August 2012)

Volume 10, Issue 5, Pages (February 2015)

Presentation transcript:

An Essential Role for IFN-γ in Regulation of Alloreactive CD8 T Cells Following Allogeneic Hematopoietic Cell Transplantation Wannee Asavaroengchai, Hui Wang, Shumei Wang, Lan Wang, Roderick Bronson, Megan Sykes, Yong-Guang Yang Biology of Blood and Marrow Transplantation Volume 13, Issue 1, Pages 46-55 (January 2007) DOI: 10.1016/j.bbmt.2006.09.014 Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 IFN-γ inhibits GVHD induced by donor CD8 T cells. Recipient B6D2F1 mice were lethally irradiated and reconstituted with 7 × 106 TCD BMCs and 3 × 107 CD4-depleted spleen cells from WT (WT GVHD; n = 15) or GKO (GKO GVHD; n = 19) B6 donors. Non-GVHD controls were lethally irradiated B6D2F1 mice that received TCD BMC alone or with TCD splenocytes from WT (WT-Ctrl; n = 8) or GKO (GKO-Ctrl; n = 8) donors. Data from 3 independent experiments are combined. The percentages of CD8+ cells in WT and GKO allo-HCT inocula (ie, CD4-depleted splenocytes) used in these experiments were 17.9% and 17.7%, 16.1% and 15.7%, and 21% and 23%, respectively. Shown are (A) percent survival and (B) mean body weight changes (mean ± SDs) of the allo-HCT recipients. Mean weight changes = [(current weight/weight at day 0) − 1]. *P < .05. Biology of Blood and Marrow Transplantation 2007 13, 46-55DOI: (10.1016/j.bbmt.2006.09.014) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 GKO allo-HCT induces more severe GVHD pathology. Shown are pathologic GVHD scores (mean ± SD, n = 3-6/group) and representative H&E photomicrographs of the lungs (A), liver (B), and colon (C) from the recipients of WT allo-HCT (solid columns) or GKO allo-HCT (open columns). *P < .05. D, Immunofluorescent staining of liver sections prepared from allo-HCT recipients at day 7 with anti-CD8. Three mice from each group were analyzed and representative photomicrographs are shown. Biology of Blood and Marrow Transplantation 2007 13, 46-55DOI: (10.1016/j.bbmt.2006.09.014) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Augmented activation and expansion of donor CD8 T cells in the recipients of GKO allo-HCT. A, B, Expression of activation markers on donor CD8 T cells in the spleens of lethally irradiated B6D2F1 mice receiving allo-HCT from WT or GKO B6 donors (n = 6/group). A, Percentages of donor CD25+, CD62L−, and CD44high CD8 T cells at the indicated time points. WT and GKO donor CD8 T cells are presented as solid and open bars, respectively. B, Representative flow cytometric profiles display the expression of CD25, CD62L, and CD44 on gated donor CD8 T cells at day 4. Thick lines represent the isotype staining controls. Analysis gates were set based on staining profiles of appropriate isotype control mAs and naive splenocytes were stained with the same mAbs at the same time. C, Spleen cells were prepared from B6D2F1 recipients of allo-HCT from WT (solid bars) or GKO (open bars) 2C donors at the indicated time points, and the percentages of CD25+ and CD62L− 2C T cells were analyzed by flow cytometric analysis. Data are shown as mean ± SD (n = 3/group). *P < .05; **P < .01. Biology of Blood and Marrow Transplantation 2007 13, 46-55DOI: (10.1016/j.bbmt.2006.09.014) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Effect of IFN-γ on apoptosis of donor CD8 T cells. Spleen cells were prepared from the recipients of WT (solid bars) or GKO (open bars) allo-HCT at the indicated time points, and the percentages of apoptotic donor CD8 (or 2C) T cells were determined by flow cytometric analysis. A, Percentages of apoptotic donor CD8 T cells in the spleens of B6 → B6D2F1 HCT recipients. B, Percentages of apoptotic donor 2C T cells in the spleens of 2C →; B6D2F1 HCT recipients. Data are shown as mean ± SD (n = 3-6/group). *P < .05; **P < .01. Biology of Blood and Marrow Transplantation 2007 13, 46-55DOI: (10.1016/j.bbmt.2006.09.014) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Effect of IFN-γ on division of donor CD8 T cells. A, B, B6D2F1 mice received BMCs and CSFE-labeled CD4-depleted spleen cells from WT (solid bars) or GKO (open bars) B6 donors (n = 3/group). Recipient spleen and lymph node cells were prepared at the indicated time points and analyzed for division of donor CD8 T cells. A, Numbers of donor CD8 T cells with each division in the spleen at days 2 and 4 and in the lymph nodes at day 4 after HCT. Axillary, brachial, and inguinal lymph nodes were harvested at the indicated time points, and pooled lymph node cells were analyzed. B, Representative histograms show CFSE levels in gated donor CD8 T cells at day 4. Numbers indicate percentages of cells with each number of cell divisions. C, B6D2F1 mice received BMCs and CFSE-labeled spleen cells from WT (solid bars) or GKO (open bars) 2C donors (n = 3/group). Data shown are percentages of donor 2C TCR+ cells with different cell divisions (mean ± SD) in the recipient spleen at day 4 after HCT. *P < .05; **P < .01; ***P < .001. Biology of Blood and Marrow Transplantation 2007 13, 46-55DOI: (10.1016/j.bbmt.2006.09.014) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 Comparison of Treg, NKT, and memory T cells in normal WT and GKO B6 mice. Spleen cells were prepared from naive WT (solid bars) and GKO (open bars) B6 mice (8 wk old; n = 3/group) and analyzed for Treg, NKT, and memory T cells by flow cytometry. A, Percentages of total (CD3+Foxp3+), CD4 (CD4+Foxp3+), CD8 (CD8+Foxp3+), and CD4− (CD4−Foxp3+) Treg cells. B, Percentages of total (CD3+NK1.1+), CD4 (CD4+CD3+NK1.1+), CD8 (CD8+CD3+NK1.1+), and double-negative (CD4−CD8−CD3+NK1.1+) NKT cells. C, Percentages of CD4 and CD8 central (CD44+CD62L+) and effector (CD44+CD62L−) memory T cells. Results are presented as mean ± SD. *P < .05; **P < .01. Biology of Blood and Marrow Transplantation 2007 13, 46-55DOI: (10.1016/j.bbmt.2006.09.014) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions